Veloxis Pharmaceuticals Initiates First Patient Dosing in Phase 2 RENGEVITY-201 Trial for Pegrizeprument to Prevent Organ Rejection in Kidney Transplant Recipients

September 6, 2026

Asahi Kasei Corporation USA

Overview

Veloxis Pharmaceuticals, an Asahi Kasei Group company, has commenced dosing the first patient in its Phase 2 clinical trial, “RENGEVITY-201,” for Pegrizeprument, an investigational drug aimed at preventing organ rejection in kidney transplant recipients. This trial seeks to suppress post-transplant rejection and improve long-term patient outcomes, addressing a significant unmet medical need in transplant medicine. The initiation of this Phase 2 study marks a crucial step in evaluating the drug’s efficacy and safety, with future results eagerly anticipated by the medical community.

In Depth

Key Findings

Veloxis Pharmaceuticals, a member of the Asahi Kasei Group, has successfully initiated dosing for the first patient in its Phase 2 clinical trial, “RENGEVITY-201,” for Pegrizeprument. This investigational drug is designed to prevent organ rejection in kidney transplant recipients. This significant milestone underscores the company’s commitment to addressing the unmet medical needs within the transplant medicine field.

Technical Details

The RENGEVITY-201 trial is planned as a multi-center, open-label, non-controlled study, primarily aimed at evaluating the safety, tolerability, and pharmacokinetics of Pegrizeprument in patients who have undergone kidney transplantation. This Phase 2 study will also collect preliminary efficacy data to establish a recommended dose and dosing schedule for Pegrizeprument, paving the way for larger-scale clinical trials. Pegrizeprument is a novel immunosuppressant candidate designed to suppress rejection by targeting specific immune pathways. It is anticipated to potentially reduce the side effects associated with conventional immunosuppressive therapies while improving the long-term survival rates of transplanted organs. While the exact number of patients is not yet disclosed, the study targets adult patients who have received a kidney transplant.

Background & Context

Kidney transplantation significantly improves the quality of life for patients with end-stage renal disease; however, post-transplant organ rejection remains a serious challenge, contributing to lower graft survival rates and increased patient mortality risk. While current immunosuppressants are effective, concerns persist regarding their side effects, such as increased infection risk and nephrotoxicity, which can impact patients’ long-term health. Consequently, the development of safer and more effective novel immunosuppressive therapies is a pressing need. Veloxis Pharmaceuticals, as a company dedicated to transplant medicine, aims to provide innovative solutions in this area.

Strategic Significance & Outlook

The progress of the RENGEVITY-201 trial is critically important in determining the future role of Pegrizeprument in transplant medicine. If successful, Pegrizeprument could become a new therapeutic option that improves the quality of life for kidney transplant patients and promotes long-term graft survival. Veloxis Pharmaceuticals plans to engage with regulatory authorities based on the trial results and proceed to further development stages. The advancement of this clinical trial holds significant strategic importance for the entire Asahi Kasei Group’s healthcare business strategy.

Source: https://www.asahi-kasei.com/news/2026

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.